- Home
- CMPX
as 11-15-2024 4:00pm EST
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 236.7M | IPO Year: | N/A |
| Target Price: | $7.67 | AVG Volume (30 days): | 513.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.77 - $2.34 | Next Earning Date: | 11-12-2024 |
| Revenue: | $850,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 747.71% |
Latest Compass Therapeutics Inc. News
CMPX Breaking Stock News: Dive into CMPX Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Compass Therapeutics to Participate in Upcoming Investor Events
GlobeNewswire
5 days ago
Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update
GlobeNewswire
9 days ago
Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Simply Wall St.
12 days ago
US Penny Stocks To Watch: 3 Picks With Market Caps Over $40M
GlobeNewswire
a month ago
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
GlobeNewswire
2 months ago
Compass Therapeutics to Participate in Upcoming Investor Events
Simply Wall St.
3 months ago
Institutional investors own a significant stake of 50% in Compass Therapeutics, Inc. (NASDAQ:CMPX)
GlobeNewswire
3 months ago
Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update
Compare CMPX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CMPX Compass Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.